Inverse relationship between p-glycoprotein expression and its proliferative activity in hepatocellular carcinoma

Oncology (Switzerland)

Volumn 54, Issue 3, 1997, Pages 231-237

  Takanishi, Kijuro ^a   Miyazaki, Masaru ^a   Ohtsuka, Masayuki ^a   Nakajima, Nobuyuki ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

Hepatocellular carcinoma; Immunohistochemistry; Ki 67; P glycoprotein; Proliferative activity

Indexed keywords

GLYCOPROTEIN P; KI 67 ANTIGEN; MONOCLONAL ANTIBODY;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; FROZEN SECTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIVER CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AGED; CARCINOMA, HEPATOCELLULAR; CELL DIVISION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MALE; MIDDLE AGED; P-GLYCOPROTEIN;

EID: 0030975241     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000227694     Document Type: Article

References (37)

1. Gozzetti G, Mazziotti A, Cavallari A, et al: Hcpatic resection for tumors in cirrhotic livers, lnt Surg 1987;72:82-86.
2. Bismuth H, Houssin D, Ornowski J, et al: Liver resections in cirrhotic patients: A western experience, World J Surg 1986:10:311-317.
3. Pichlmaycr R: Is there a place Tor liver grafting for malignancy? Transplant Proc 1988:20:478-482.
4. Kasugai H, Kojima J, Tatsuta M, et al: Treatment of hepatoccllular carcinoma by transcatheter arterial embolization combined with intra-artcrial infusion of mixture of cisplatin and ethiodized oil, Gastroenterology 1989:97: 965-971.
5. Kanematsu T, Furuta T, Takenaka K, et al: A 5-year experience of lipiodolization: Selective regional chemotherapy for 200 patients with hepatoccllular carcinoma, Hepatology 1989; 10:98-102.
6. Vetter D, Wenger JJ, Bergier JM, et al: Trans-catheter oily chcmocmbolization in the management of advanced hepatoccllular carcinoma in cirrhosis: Results of a western comparative study in 60 patients, Hepatology 1991:13:427-433.
7. Stefanini GF, Amorati P, Biselli M, et al: Efficacy of transarterial targeted treatments on survival of patients with hepatocellular carcinoma: An Italian experience, Cancer 1995:75: 2427-2434.
8. Shiina S, Tagawa K, Unuma T, et al: Percutaneous ethanol injection for the treatment of small hepatoccllular carcinoma: Analysis of 77 patients, AJR 1990:155:1221-1226.
9. Ebara M, Ohto M, Sugiura N, et al: Percutaneous ethanol injection for the treatment of small hepatocellular carcinoma, J Gastroenterol Hepatol 1990:5:616-626.
10. Livraghi T, Bolondi L, Lazzaroni S, et al: Percutaneous ethanol injection in the treatment of hepatoccllular carcinoma: A study on 207 patients, Cancer 1992:68:926-929.
11. DeVita VT Jr, Young RY, Cancllos GP: Combination versus single agent chemotherapy: A review of the basis for selection of drug treatment of cancer, Cancer 1975:35:98-110.
12. Gottesman MM: How cancer cells evade chemotherapy: Sixteenth Richard and Hinda Rosenthal Foundation Award I.ecturc, Cancer Res 1993:53:747-754.
13. Juliano RL, Ling V: A surface glycoprotein in modulating drug permeability in Chinese hamster ovary cell mutants, Biochim Biophys Acta 1976:455:152-162.
14. Endicott JA, Ling V: The biochemistry of P-glycoprotein-mcdiated multidrug resistance, Annu Rev Biochem 1989;58:137-171.
15. Thorgeirsson SS, Huber BE, Sorrell S, et al: Expression of the multidrug resistant gene in hcpatocarcinogenesis and regenerating rat liver, Science 1987:236:1120-1122.
16. Fairchild CR, Ivy SP, Rushmore T, et al: Car-cinogen-induced mdr overexprcssion is associated with xenobiotic resistance in rat preneo-plastic liver nodules and hepatocellular carcinoma, Proc Natl Acad Sci USA 1987:84:7701-7705.
17. Burt RK, Garfield S, Johnson K, et al: Transformation of rat liver epithelial cells with v-H-ras or v-raf causes expression of MDR-1, gluta-thionc-S-transfcrase-P and increased resistance to cytotoxic chemicals, Carcinogenesis 1988:9: 2329-2332.
18. Bradley G, Sharma R, Rajalakshmi S, Ling V: P-glycoprotcin expression during tumor progression in the rat liver, Cancer Res 1992:52: 5154-5161.
19. Chin KV, Ucda K, Pastan I, et al: Modulation of activity of the promoter on the human MDR1 gene by Ras and p53, Science 1992: 255:459-462.
20. Marino PA, Gottesman MM, Pastan I: Regulation of the multidrug resistance gene in regenerating rat liver, Cell Growth Differ 1990:1: 57-62.
21. Mickley LA, Bates SE, Richert ND, et al: Modulation of the expression of a multidrug resistance gene (mdr-l/P-glycoprotein) by differentiating agents, J Biol Chem 1989:264:18031-18040.
22. Nagasue N, Dhar DK, Makino Y, et al: Overexprcssion of P-glycoprotein in adenomatous hyperplasia of human liver with cirrhosis, J Hepatol 1995;22:197-201.
23. Park JG, Lee SK, Hong IG, et al: MDR I gene expression: Its effect on drug resistance to doxorubicin in human hepatoccllular carcinoma cell lines, J Natl Cancer Inst 1994:86:700-705.
24. Ishiiki K, Nakano A, Ito M, et al: P-glycopro-tein expression in hepatocellular carcinoma, J Surg Oncol 1993:52:21-25.
25. Itsubo M, Ishikawa T, Toda G, et al: Immuno-histochcmical study of expression and cellular localization of the multidrug resistance gene product P-glycoprotcin in primary liver carcinoma, Cancer 1994:73:298-303.
26. Hsu SM, Raine L, Fänger H: Use of avidin-bio-tin-peroxidase complex (ABC) in immunopcr-oxidase techniques: A comparison between ABC and unlabeled antibody (PAP) procedures, J Histochem Cytochcm 1981:4:581-584.
27. Gerdcs J, Schwab U, Lemke H, et al: Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation, Int J Cancer 1983;31:13-20.
28. Gcrdes J, Dallenbach F, Lennert K, et al: Growth fractions in malignant non-Hodgkin's lymphomas (NHL) as determined in situ with the monoclonal antibody Ki-67, Hematol Oncol 1984:2:365-371.
29. Gerdes J, Lemke H, Baisch H, et al: Cell cycle analysis of a proliferation-associated human nuclear antigen defined by the monoclonal an-tibodv Ki-67, J Immunol 1984.133:1710-1715.
30. World Health Organization: Histological Typing of Tumours of the Liver, cd 2, Berlin, Springer, 1994.
31. Fojo AT, Ucda K, Slamon DJ, et al: Expression of a multidrug-rcsistance gene in human tumors and tissues, Proc Natl Acad Sci USA 1987:84:265-269.
32. Thiebaut F, Turuo T, Hamada H, ct al: Cellular localization of the multidrug-rcsistance gene product P-glycoprotein in normal human tissues, Proc Natl Acad Sei USA 1987:84:7735-7738.
33. Chan HSL, Thomer PS, Haddad G, et al: Immunohistochemical detection of P-glycopro-tein prognostic correlation in soft tissue sarcoma of childhood, J Clin Oncol 1990:8:689-704.
34. Chan HSL, Haddad G, Thomer PS, ct al: P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma, N Engl J Med 1991;325:1608-1614.
35. Radcrcr M, Scheithauer W: Clinical trials of agents that reverse multidrug resistance: A literature review, Cancer 1993;72:3553-3563.
36. Leyland-Joncs B, Dalton W, Fisher GA, ct al: Reversal of multidrug resistance to cancer chemotherapy, Cancer 1993,72:3484-3488.
37. Miyazaki M, Shimoda T, Itoh H, et al: Enhancement of doxorubicin by verapamil in the hepatic artery infusion for liver tumors in rats, Cancer 1993:72:349-354.